{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/prescribing-information/cromones/","result":{"pageContext":{"chapter":{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones","depth":2,"htmlHeader":"<!-- begin field 3fa170a2-44a5-42a0-9123-a6d7016c3ae0 --><h2>Cromones</h2><!-- end field 3fa170a2-44a5-42a0-9123-a6d7016c3ae0 -->","summary":"","htmlStringContent":"<!-- begin item acd10a80-cd5b-46a0-8c0b-a6d7016c3582 --><!-- end item acd10a80-cd5b-46a0-8c0b-a6d7016c3582 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"eca71bd6-cb0d-52df-9415-b637fa22f190","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field ae78eeb7-0265-4d94-aa6f-a6f700ecff0f --><h3>What dose should be given?</h3><!-- end field ae78eeb7-0265-4d94-aa6f-a6f700ecff0f -->","summary":"","htmlStringContent":"<!-- begin item b3d0888e-10c5-404b-9f41-a6f700ecf915 --><!-- begin field 707749f2-81fc-4a73-bf98-a6f700ecff0f --><ul><li><strong>Cromones (sodium cromoglicate and nedocromil sodium) can be considered as add-on treatments for asthma. They are delivered via pressurized metered dose inhalers</strong>.<ul><li>Advise people that inhaled sodium cromoglicate or nedocromil sodium should be used regularly. Doses are as follows for children aged over 5 years and adults.<ul><li>Sodium cromoglicate - Initially 10 mg four times a day, additional dose may also be taken before exercise, increased if necessary to 10 mg six to eight times a day. Maintenance dose is 5 mg four times a day (5 mg is equivalent to one puff).</li><li>Nedocromil sodium- Initially 4 mg four times a day, when control achieved, may be possible to reduce to twice daily (4 mg is equivalent to 2 puffs). </li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>] </p><!-- end field 707749f2-81fc-4a73-bf98-a6f700ecff0f --><!-- end item b3d0888e-10c5-404b-9f41-a6f700ecf915 -->","subChapters":[]},{"id":"25e7fa7f-81fb-54f4-9d88-f4dbafef0377","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9bcd825d-0b99-4a2a-b271-a6db00b60fe9 --><h3>Contraindications and cautions</h3><!-- end field 9bcd825d-0b99-4a2a-b271-a6db00b60fe9 -->","summary":"","htmlStringContent":"<!-- begin item 7924c31f-2be2-4c22-b1d7-a6db00b60ac0 --><!-- begin field 25023564-d199-475d-9117-a6db00b60fe9 --><ul><li>Cromone therapy should be discontinued if the person develops eosinophilic pneumonia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 25023564-d199-475d-9117-a6db00b60fe9 --><!-- end item 7924c31f-2be2-4c22-b1d7-a6db00b60ac0 -->","subChapters":[]},{"id":"5597ae37-90d9-5b1f-be76-79c011d44e1e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7fe150e4-d1ad-4efb-9132-a6db00b41505 --><h3>Adverse effects</h3><!-- end field 7fe150e4-d1ad-4efb-9132-a6db00b41505 -->","summary":"","htmlStringContent":"<!-- begin item 12b79e14-cec9-46d8-8246-a6db00b40fbd --><!-- begin field 200b1977-df16-40de-9570-a6db00b41505 --><ul><li><strong>Adverse effects of cromones include:</strong><ul><li>Mild throat irritation, coughing, and bronchospasm.<ul><li>If inhalation of a cromone causes bronchospasm, advise the person to use their short-acting beta-2 agonist inhaler (salbutamol or terbutaline) and discontinue cromone treatment.</li></ul></li><li>Headache and rhinitis have also been reported in clinical trials.</li><li>Hypersensitivity reactions, including angioedema, bronchospasm, hypotension and collapse have been reported extremely rarely in patients using inhaled sodium cromoglicate.</li><li>Very rare cases of eosinophilic pneumonia have been reported.</li></ul></li><li><strong>Adverse effects of nedocromil sodium also include:</strong><ul><li>Abdominal pain, vomiting, nausea.</li><li>Dyspepsia.</li><li>Altered sense of taste.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2014b</a>]</p><!-- end field 200b1977-df16-40de-9570-a6db00b41505 --><!-- end item 12b79e14-cec9-46d8-8246-a6db00b40fbd -->","subChapters":[]},{"id":"e20e6f03-65b5-5dbb-8c82-810fc85d6c49","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 45aede2c-1ada-4760-863d-a6db00b6471c --><h3>Drug interactions</h3><!-- end field 45aede2c-1ada-4760-863d-a6db00b6471c -->","summary":"","htmlStringContent":"<!-- begin item 970d1bf1-38c5-4df6-8d17-a6db00b6427f --><!-- begin field 028321b5-a47e-4fcc-9f03-a6db00b6471c --><ul><li>No harmful drug interactions have been observed with cromones.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 028321b5-a47e-4fcc-9f03-a6db00b6471c --><!-- end item 970d1bf1-38c5-4df6-8d17-a6db00b6427f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}